BioTech Medicines – M A N O X B L O G

Take a look at five biotechs with major catalysts to report earnings

Biotechs are heading into the second quarter earnings period ready to pressure their Big Pharma peers with new drug launches. More than ever, smaller biotechs are choosing to go at…

admin August 4, 2026

Biologic Drugs BioTech Medicines

The U.S. biotechnology sector is ceding dominance to China

China has been strategically growing its biotech sector for years, increasingly becoming a source of in-licensed or partnered drugs for Big Pharma. At the same time, the U.S. government has…

admin July 27, 2026

Biologic Drugs BioTech Medicines

Biopharma strikes 50+ M&As deals in H1, led by Lilly’s $25B spend

The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back. Nine deals…

admin July 2, 2026

Biologic Drugs BioTech Medicines Pharmaceutical

Beyond better chemistry: The evolution of pharma process development

The integration of chemical engineering into process development has transformed how companies scale, control, and optimize manufacturing for a new generation of therapies. Over the past three decades, pharmaceutical manufacturing…

admin June 29, 2026

Biologic Drugs BioTech Medicines

US biotech leadership at risk as China dominates manufacturing

Chinese biopharma companies lead when it comes to manufacturing scale, CDMO capacity, and raw materials, according to analyses from the Cure Innovation Index. America’s biotechnology leadership is in jeopardy due…

admin June 26, 2026

Biologic Drugs BioTech Medicines

Ebola’s Crisis: A Biotech’s Radical Plea to Sidestep Science’s Pace

900+ confirmed cases of Bundibugyo Ebola in DRC, with 230+ deaths (26% fatality rate). No approved treatment exists for this strain, leaving patients with only supportive care. 309-patient trial showed…

admin June 24, 2026

Biologic Drugs BioTech Medicines Pharmaceutical

Pharma-to-CDMO facility sales have accelerated in recent months

CDMOs turn to pharma facility acquisitions amid manufacturing realignment. A wave of facility sales to CDMOs reflects shifting manufacturing strategies as drugmakers expand U.S. production and outsourcing partners scale capacity.…

admin May 20, 2026

Biologic Drugs BioTech Medicines Pharmaceutical

Lilly vs. Pfizer: Acquisition spree comparison

Lilly’s plans to buy CAR-T firm Kelonia in deal worth up to $7 billion. GLP-1 revenue at Eli Lilly and Novo Nordisk, 2022-2025. Lilly’s tirzepatide franchise grew more than fivefold…

admin April 29, 2026

Biologic Drugs BioTech Medicines

mAB production:: Series Wrap‑Up – The Complete Manufacturing Journey of a Monoclonal Antibody

From a single gene in a plasmid to a vial in the patient’s hand: reflections on the 11 steps that make biologic medicines possible. Over the past weeks, we have…

admin April 27, 2026

Biologic Drugs BioTech Medicines

mAB production: Step 11 – Sterile Filling and Finishing: From Bulk Drug Substance to Patient‑Ready Vial

How we sterile‑filter, fill, inspect, label, and package the monoclonal antibody under aseptic conditions. Welcome back to our deep‑dive series on monoclonal antibody manufacturing. In Step 10, we performed ultrafiltration…

admin April 23, 2026